Cutler Group LP Nektar Therapeutics Put Options Transaction History

Cutler Group LP

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2022 Oct 25, 2022	SELL	$3.04 - $5.14 $8,512 - $14,392	-2,800 Reduced 58.33%	2,000 $3,000
Q2 2022 Aug 04, 2022	SELL	$3.17 - $6.17 $312,879 - $608,979	-98,700 Reduced 95.36%	4,800 $8,000
Q1 2022 Apr 14, 2022	BUY	$4.16 - $13.72 $427,232 - $1.41 Million	102,700 Added 12837.5%	103,500 $67,000
Q4 2021 Jan 18, 2022	SELL	$10.83 - $18.41 $55,233 - $93,891	-5,100 Reduced 86.44%	800 $1,000
Q1 2020 May 07, 2020	BUY	$14.47 - $27.96 $81,032 - $156,576	5,600 Added 1866.67%	5,900 $20,000
Q1 2019 May 10, 2019	SELL	$31.58 - $46.35 $173,690 - $254,925	-5,500 Reduced 94.83%	300 $0
Q3 2018 Nov 07, 2018	SELL	$46.46 - $68.49 $854,864 - $1.26 Million	-18,400 Reduced 76.03%	5,800 $16,000
Q2 2018 Aug 10, 2018	BUY	$46.25 - $104.45 $906,500 - $2.05 Million	19,600 Added 426.09%	24,200 $131,000
Q1 2018 May 11, 2018	SELL	$57.4 - $108.44 $631,400 - $1.19 Million	-11,000 Reduced 70.51%	4,600 $1,000
Q4 2017 Jan 17, 2018	BUY	$23.02 - $60.5 $359,112 - $943,800	15,600	15,600 $9,000

140

135M

32.8K

55.5K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $244M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.